Item 5.07. Submission of Matters to a
Vote of Security Holders.
On January 31, 2022, iBio, Inc. (the “Company”)
reconvened it 2021 Annual Meeting of Stockholders (the “Annual Meeting”), which had previously been adjourned on December
9, 2021 and again on December 22, 2021 to allow more stockholders to consider and vote on: (i) Proposal 4–Approval of an amendment
to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding
shares of common stock, $0.001 par value per share (the “Common Stock”), at a ratio of one (1) share of Common Stock for every
ten (10) shares of Common Stock (the “Reverse Stock Split”), and (ii) Proposal 5–Approval of an amendment to the Company’s
Certificate of Incorporation, as amended, to decrease, concurrent with and conditioned upon the effectiveness of the Reverse Stock Split,
the number of authorized shares of the Company’s Common Stock from 275,000,000 to 55,000,000. Based on the tabulation of votes,
Proposals 4 and 5 did not receive the requisite votes and did not pass. The final results received by the Company for Proposals 4 and
5 are set forth below.
As previously reported in the Company’s
Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on December 10, 2021, the
Company’s stockholders voted at the Annual Meeting held on December 9, 2021 to approve Proposal 1 (Director Election Proposal),
Proposal 2 (Auditor Ratification Proposal), Proposal 3 (Say-on Pay Proposal) and 6 (the Adjournment Proposal). The proposals are
described in detail in the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting, which was filed with the
Commission on October 26, 2021.
Proposal 4–Approval of an amendment to
the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding
shares of common stock, $0.001 par value per share (the “Common Stock”), at a ratio of one (1) share of Common Stock for every
ten (10) shares of Common Stock (the “Reverse Stock Split”)
Based on the tabulation of votes, Proposal 4
did not receive the requisite votes and did not pass. The results of the voting for this proposal were as follows:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
89,131,647
|
|
14,381,107
|
|
1,467,944
|
|
0
|
Proposal 5–Approval of an amendment to
the Company’s Certificate of Incorporation, as amended, to decrease, concurrent with and conditioned upon the effectiveness of the
Reverse Stock Split, the number of authorized shares of the Company’s Common Stock from 275,000,000 to 55,000,000
Based on the tabulation of votes, Proposal 5 did
not receive the requisite votes and did not pass. The results of the voting for this proposal were as follows:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
92,855,714
|
|
41,924,628
|
|
2,200,356
|
|
0
|
Although approximately
65% of the shares voted (including abstentions and withheld votes) were voted in favor of Proposal 4 and approximately 68% of the shares
voted (including abstentions and withheld votes) were voted in favor of Proposal 5, the Company did not have the requisite stockholder
votes to approve the proposals. The Company plans to continue to work on solutions to overcome structural impediments to implementation
of the will of its stockholders.